Pertuzumab (Perjeta / Phesgo)
An anti-HER2 monoclonal antibody given with trastuzumab and chemotherapy for HER2-positive breast cancer — a cornerstone of dual HER2 blockade.
What is Pertuzumab?
What it targets
The HER2 receptor (subdomain II). Pertuzumab blocks HER2 from pairing with HER3, shutting down a key growth signal in HER2-positive breast cancer cells.
Who it may help
Patients with confirmed HER2-positive breast cancer — first-line metastatic disease, and selected early-stage cancers before or after surgery — with adequate heart function.
Why testing matters
HER2 status must be confirmed by IHC and/or ISH/FISH before treatment. Pertuzumab does not work in HER2-negative breast cancer, so accurate testing is essential.
Which cancers can Pertuzumab treat?
Pertuzumab is approved for HER2-positive breast cancer across several settings, always as part of a combination regimen.
| HER2-positive metastatic breast cancer (first-line) | Approved with trastuzumab and docetaxel for patients not previously treated with anti-HER2 therapy or chemotherapy for metastatic disease (the CLEOPATRA regimen). |
| HER2-positive early breast cancer — neoadjuvant | Approved with trastuzumab and chemotherapy before surgery for locally advanced, inflammatory, or early-stage disease (tumour over 2 cm or node-positive). |
| HER2-positive early breast cancer — adjuvant | Approved with trastuzumab and chemotherapy after surgery for patients at high risk of recurrence, to lower the chance of the cancer returning. |
| First-line metastatic with trastuzumab deruxtecan | Pertuzumab combined with trastuzumab deruxtecan (Enhertu) is now an approved first-line option for unresectable or metastatic HER2-positive disease, based on DESTINY-Breast09. |
| Other HER2-positive cancers | Not a routine standard use outside breast cancer; any off-label or trial use should be decided only by a specialist after full review. |
Are you eligible for Pertuzumab?
Pertuzumab is suitable only when HER2 testing confirms the cancer is HER2-positive and the heart is healthy enough for anti-HER2 therapy.
- HER2-positive breast cancer confirmed by IHC (score 3+) and/or ISH/FISH amplification
- Metastatic disease planned for first-line anti-HER2 therapy, or early-stage disease suitable for neoadjuvant or adjuvant dual HER2 blockade
- Hormone receptor (ER and PR) status known, as it affects the wider treatment plan
- Adequate baseline heart function, usually a normal left ventricular ejection fraction on echocardiogram or MUGA
- Able to receive companion chemotherapy and trastuzumab, since pertuzumab is not used alone
- No active uncontrolled heart failure or severe heart disease that makes anti-HER2 therapy unsafe
- Not pregnant, with effective contraception in place during and after treatment
- No serious prior allergic reaction to pertuzumab, trastuzumab, or other monoclonal antibody therapy
How does Pertuzumab work?
- HER2 drives the cancer
- Pertuzumab blocks HER2 pairing
- Dual blockade with trastuzumab
- Recruiting the immune system
Pertuzumab and trastuzumab grip HER2 at two different points — together they block the receptor far more completely than one antibody can alone.
Tests required before starting Pertuzumab
These tests confirm HER2 status, plan the regimen, and establish a heart-function baseline for safe monitoring.
| HER2 testing (IHC and ISH/FISH) | Confirms the cancer is HER2-positive — the single most important test, since pertuzumab does not work in HER2-negative disease |
| ER and PR hormone receptor testing | Determines hormone receptor status, which shapes whether endocrine therapy is added later in the plan |
| Echocardiogram or MUGA scan | Measures baseline heart pumping strength (LVEF) before anti-HER2 therapy and is repeated during treatment |
| Staging imaging (CT, PET-CT, bone scan) | Defines the extent of disease and whether it is early-stage or metastatic, guiding the treatment setting |
| Complete Blood Count (CBC) | Baseline white cell, platelet, and haemoglobin counts — monitored during the chemotherapy-containing regimen |
| Liver and kidney function tests | Assess organ function and fitness for the full combination regimen including chemotherapy |
| Pregnancy test (where relevant) | Pertuzumab can harm an unborn baby — pregnancy must be excluded before starting and prevented during treatment |
How is Pertuzumab given?
Pertuzumab is given by vein at an infusion centre, usually every 3 weeks alongside trastuzumab and chemotherapy. A subcutaneous combination (Phesgo) is also available.
| Loading dose (IV) | 840 mg as a 60-minute intravenous infusion for the first cycle |
| Maintenance dose (IV) | 420 mg every 3 weeks, infused over about 30 to 60 minutes |
| Subcutaneous option (Phesgo) | Fixed-dose pertuzumab plus trastuzumab given as a single under-the-skin injection over a few minutes, instead of two IV infusions |
| Given with | Trastuzumab and chemotherapy (often docetaxel); the exact partners depend on the setting and the oncologist's plan |
| Observation | Patients are watched during and after infusion, especially the first dose, for infusion-related reactions |
| Duration | Continued for a set number of cycles in early breast cancer, or until progression or unacceptable side effects in metastatic disease |
Clinical evidence and benefits
Adding pertuzumab to trastuzumab and chemotherapy has improved outcomes across the metastatic, neoadjuvant, and adjuvant settings in major trials.
| Metastatic disease (CLEOPATRA) | Adding pertuzumab to trastuzumab and docetaxel substantially extended the time before the cancer progressed and improved overall survival versus trastuzumab and chemotherapy alone |
| Before surgery (NeoSphere, TRYPHAENA) | Adding pertuzumab raised the rate of complete tumour disappearance (pathological complete response) achieved before surgery in HER2-positive early breast cancer |
| After surgery (APHINITY) | Adjuvant pertuzumab with trastuzumab and chemotherapy further lowered the risk of the cancer returning in selected high-risk early breast cancer patients |
| New first-line option (DESTINY-Breast09) | Pertuzumab combined with trastuzumab deruxtecan nearly doubled the time before progression compared with the long-standing taxane-trastuzumab-pertuzumab standard in first-line metastatic disease |
| More convenient delivery (Phesgo) | The subcutaneous fixed-dose combination matched the efficacy of IV pertuzumab plus trastuzumab while cutting treatment chair time to minutes |
Individual responses vary with stage, HER2 status, hormone receptor status, prior treatment, and overall health. These reflect published clinical trial data.
Side effects of Pertuzumab
Many side effects come from the chemotherapy that pertuzumab is partnered with. Most are manageable, but heart function and infusion reactions need close attention.
| Diarrhoea | Very common, especially with the chemotherapy partner — usually managed with diet changes and anti-diarrhoeal medicine |
| Hair loss (alopecia) | Common, driven mainly by the chemotherapy given alongside pertuzumab rather than the antibody itself |
| Nausea and vomiting | Common — anti-sickness medicines are given before and after infusions to control it |
| Fatigue / weakness | Common during treatment cycles; often improves between cycles and after treatment ends |
| Low white cell count | Neutropenia raises infection risk — blood counts are monitored and fever must be reported urgently |
| Anaemia | Low red cell counts can cause tiredness and breathlessness; checked on routine blood tests |
| Skin rash | Common — usually mild and managed with simple skin care or antihistamines |
| Mouth sores (mucositis) | Can occur with the chemotherapy partner; good mouth care and rinses help |
| Peripheral neuropathy | Numbness or tingling in hands and feet, mainly from the taxane chemotherapy partner |
| Reduced heart function | Anti-HER2 antibodies can lower the heart's pumping strength; usually reversible and monitored with regular heart scans |
| Infusion-related reactions | Fever, chills, or flushing during infusion, most likely with the first dose — patients are observed closely |
Contact your doctor immediately if you develop:
- New or worsening shortness of breath, ankle swelling, or sudden weight gain (possible heart problem)
- Chest pain or a fast or irregular heartbeat
- Severe or persistent diarrhoea, or signs of dehydration
- High fever, chills, or any sign of infection with low blood counts
- Signs of a severe allergic or infusion reaction such as breathing difficulty, dizziness, or swelling of the face or throat
Safety precautions and key cautions
Tell your oncologist about your heart history, other medicines, and any chance of pregnancy before and during treatment with pertuzumab.
- Heart disease, reduced ejection fraction, high blood pressure, or prior heart failure must be disclosed — they affect whether anti-HER2 therapy is safe
- Previous anthracycline chemotherapy increases the risk of heart strain and needs careful monitoring
- Prior trastuzumab or other HER2-targeted therapy should be reviewed when planning treatment
- Pertuzumab can cause serious harm to an unborn baby — effective contraception is required during and for months after treatment
- Breastfeeding is not recommended during treatment and for a period after the last dose
- Active infection, or liver or kidney problems, should be assessed before starting the combination regimen
- Any serious allergy to monoclonal antibody therapy must be reported, as severe infusion reactions can occur
Pertuzumab combination treatments
Pertuzumab is never used alone — it is always combined with trastuzumab and other agents, with the partner depending on the treatment setting.
| Pertuzumab + trastuzumab + docetaxel | The CLEOPATRA regimen — standard first-line dual HER2 blockade for HER2-positive metastatic breast cancer |
| Pertuzumab + trastuzumab + chemotherapy | Used before surgery (neoadjuvant) and after surgery (adjuvant) in HER2-positive early breast cancer |
| Pertuzumab + trastuzumab deruxtecan | A newer first-line metastatic option from DESTINY-Breast09 that extended progression-free time beyond the older taxane-based standard |
| Phesgo (fixed-dose subcutaneous) | Pertuzumab and trastuzumab combined in one under-the-skin injection, given with or after chemotherapy depending on the setting |
| With endocrine therapy | For hormone receptor-positive, HER2-positive disease, endocrine therapy may be added after chemotherapy when appropriate |
If Pertuzumab-based treatment stops working
If HER2-positive cancer progresses during or after pertuzumab-based therapy, several effective next-line HER2 treatments are available.
| Confirm and re-test | Repeat imaging, review of original HER2 results, and sometimes a repeat biopsy, liquid biopsy, or NGS to confirm HER2 status and guide the next step |
| Trastuzumab deruxtecan (Enhertu) | A HER2 antibody-drug conjugate that is a leading next-line option and is also now used first-line in combination with pertuzumab |
| Trastuzumab emtansine (Kadcyla) | An antibody-drug conjugate option, including for patients with residual disease after neoadjuvant treatment |
| Tucatinib-based therapy | Tucatinib with trastuzumab and capecitabine is an option in later lines, including for some patients with brain metastases |
| Other HER2-directed options | Lapatinib, neratinib, margetuximab, and clinical trial regimens may be considered depending on prior therapy and country |
Cost of Pertuzumab by country
Cost depends on the number of cycles, whether the original brand or a biosimilar is used, and the companion drugs and tests involved. Biosimilars are starting to improve affordability.
| India | Branded Perjeta is expensive per cycle; biosimilar access is developing and can lower costs. Total cost also includes trastuzumab, chemotherapy, HER2 testing, and heart scans |
| USA | High per-infusion cost for branded Perjeta; the first interchangeable biosimilar (Poherdy) approved in 2025 may reduce costs over time. Manufacturer assistance programmes exist |
| UK / Europe | Covered by the NHS and national health systems for approved HER2-positive indications, typically with little or no out-of-pocket cost for eligible patients |
| China | Pertuzumab is available and biosimilars are advancing through the NMPA; some access may be supported through national or local insurance schemes |
| UAE / Gulf | Available at major cancer centres; coverage and out-of-pocket cost vary by insurance plan and emirate |
Availability of Pertuzumab globally
Pertuzumab is approved in many major cancer-treatment countries. Brand, formulation, and biosimilar status differ by region.
USA
Branded Perjeta and the subcutaneous Phesgo combination are available. Poherdy (pertuzumab-dpzb), the first interchangeable biosimilar, was approved in November 2025.
Europe / UK
Perjeta and Phesgo are approved and widely used for HER2-positive breast cancer, available through national health systems for eligible patients.
China
Pertuzumab is approved and used per CSCO and CACA guidelines. Pertuzumab biosimilars are advancing through the NMPA, expanding access in the years ahead.
India
Pertuzumab is available at major cancer centres, with biosimilar access developing through CDSCO pathways. Availability and pricing vary between hospitals and regions.
Pertuzumab in current clinical trials
Research continues into newer pertuzumab combinations, sequencing, and more convenient delivery for HER2-positive breast cancer.
| New first-line combinations | Trials such as DESTINY-Breast09 pairing pertuzumab with trastuzumab deruxtecan are reshaping the first-line metastatic standard |
| Optimising early-stage therapy | Studies refining how long and for whom neoadjuvant and adjuvant dual HER2 blockade should be used, including de-escalation strategies |
| Subcutaneous and convenience | Ongoing work on fixed-dose subcutaneous delivery (Phesgo) and home or rapid administration to ease the treatment burden |
| Biomarker-guided selection | Research into which patients benefit most from dual blockade, helping personalise treatment by HER2 and hormone receptor biology |
Your treatment journey with Pertuzumab
Diagnosis and HER2 testing
Staging and heart assessment
Treatment planning
Starting pertuzumab-based therapy
Monitoring through treatment
Response assessment
Next steps and follow-up
Questions to ask your oncologist about Pertuzumab
- Is my breast cancer confirmed HER2-positive, and by which test?
- What is the goal of treatment in my case?
- Which drugs will I receive alongside pertuzumab?
- Can I have the subcutaneous injection instead of the drip?
- How will my heart be monitored during treatment?
- How often will I have treatment, and for how long?
- Is a biosimilar available, and would it lower my costs?
- What are my options if the cancer progresses after pertuzumab?
How CancerFax supports Pertuzumab patients
CancerFax helps HER2-positive breast cancer patients understand their reports, weigh treatment options, and access pertuzumab-based care across India, China, and other countries.
| Report review | Upload your HER2, ER/PR, biopsy, and imaging reports — our team reviews them and explains what they mean for pertuzumab eligibility |
| Specialist connection | We connect patients with breast cancer oncologists experienced in HER2-positive disease and dual HER2 blockade, in India, China, and internationally |
| Second opinion | If you are unsure about your regimen, or the cancer has progressed, CancerFax arranges an expert second opinion with a breast cancer specialist |
| Treatment access | We help patients explore where pertuzumab, Phesgo, biosimilars, and next-line HER2 therapies are available, including cross-border options |
| Clinical trial matching | For metastatic or treatment-resistant HER2-positive disease, we help identify suitable clinical trials by biomarker status and prior treatment |
| International coordination | For patients seeking advanced HER2-positive breast cancer care abroad, CancerFax manages records, scheduling, travel, and follow-up |
Frequently asked questions about Pertuzumab
Common questions from patients and caregivers
Pertuzumab (Perjeta) is a targeted therapy — a monoclonal antibody that blocks the HER2 protein driving growth in HER2-positive breast cancer, rather than broadly attacking dividing cells. It is almost always given together with trastuzumab and chemotherapy, because the two antibodies block HER2 in complementary ways. Pertuzumab itself does not cause hair loss; that comes from the chemotherapy it is partnered with.
Pertuzumab and trastuzumab attach to different parts of the HER2 receptor. Pertuzumab blocks HER2 from pairing with HER3, while trastuzumab blocks a separate site. Used together they produce a more complete HER2 blockade than either antibody alone, which is why this dual blockade is the standard backbone for HER2-positive breast cancer.
Pertuzumab only helps HER2-positive breast cancer. Your tumour must be confirmed HER2-positive by IHC (a score of 3+) or by ISH/FISH testing that shows HER2 gene amplification. If your cancer is HER2-negative, pertuzumab will not work and is not used. Your oncologist will also check your heart function before starting.
Yes. Phesgo is a fixed-dose combination of pertuzumab and trastuzumab given as a single under-the-skin (subcutaneous) injection over a few minutes, instead of two separate IV infusions. It contains the same medicines and is used in the same settings. Ask your oncologist whether the subcutaneous option is available at your treatment centre.
Anti-HER2 antibodies can reduce the heart's pumping strength in some patients, which is usually reversible when caught early. This is why you will have a baseline echocardiogram or MUGA scan and repeat heart checks during treatment. Tell your team straight away about breathlessness, ankle swelling, or sudden weight gain. Most patients complete treatment without serious cardiac problems.
The first interchangeable pertuzumab biosimilar, Poherdy (pertuzumab-dpzb), was approved in the US in late 2025, and biosimilars are advancing in China and India. A biosimilar contains the same active medicine and is approved only after rigorous testing shows no clinically meaningful difference from the original Perjeta. Biosimilars can substantially lower the cost of treatment.
No. Pertuzumab can cause serious harm to an unborn baby and must not be used during pregnancy. Effective contraception is required during treatment and for several months after the last dose. Tell your oncologist immediately if you are pregnant, think you may be pregnant, or are breastfeeding, so a safe plan can be made.